AstraZeneca: Coronavirus vaccine is about 90% effective

According to the company’s announcement, the assessment of the effectiveness of the AZD1222 vaccine is based on preliminary results from phase III clinical trials in Brazil and the United Kingdom involving more than 23,000 participants. volunteers. 131 people in the study contracted infections, the vast majority of whom were people who received a placebo.

Two dosing regimens were considered in the study. 2,741 participants received half the dose first, followed by a full dose after one month, and 8,895 participants received two full doses one month apart. In the first group, the observed effectiveness was 90%, and in the second – 62%, which yielded an average effectiveness of 70% in the overall comparison.

– These results show that we have an effective vaccine that will save the lives of many people – said Prof. Andrew Pollard of the University of Oxford, head of the research group. The greater the effectiveness of the lower-dose vaccine, he added, means more people will be vaccinated.

None of the study participants who received the preparation developed a serious infection that required hospitalization. There were also no confirmed serious side effects, although the study was halted in the fall after two participants were diagnosed with serious illnesses.

The investigation is ongoing

While the trials are not yet complete – they are still ongoing in the US, Japan, Russia, South Africa, Kenya and Argentina – the company said it has begun to prepare emergency approval applications for the vaccine in a number of countries. He will also apply to the World Health Organization for inclusion in the list of vaccines that may be used, in order to speed up the availability of the preparation to poorer countries.

SEE: What Should the Covid-19 Vaccine Be? “For all people and at affordable prices”

Unlike the vaccine from Pfizer and BioNTech – the first to be effective in studies – AZD1222 does not need to be stored and transported at very low temperatures. According to AstraZeneca, it can be kept for at least 6 months in a refrigerator at 2-8 degrees Celsius.

By the end of the year, there were 4 million vaccines

AstraZeneca has announced that it will produce 4 million doses of the AZD1222 vaccine against the coronavirus by the end of the year. An additional 40 million doses should be ready by the end of the first quarter of 2021.

SEE: Third player in the COVID-19 vaccine market. Moderna is after Pfizer and Sanofi

According to Pam Cheng’s vice president, the company will have enough vaccine for 200 million doses by the end of the year and 700 million by the end of the first quarter of next year, but 4 million will be available this year. ready for use and 40 million next year. In total, AstraZeneca aims to produce 3 billion doses of the preparation by 2021.

100 million presale doses

The UK government has pre-ordered 100 million doses of the Oxford vaccine. It is enough for 50 million citizens. Health Minister Matt Hancock told the BBC Breakfast that summer will be “a little closer to normal for Britons,” but “until the vaccine is introduced we all have to fend for ourselves.”

In turn, the European Commission signed a preliminary agreement in August for the supply of 300 million doses of the vaccine with the option to purchase another 100 million.

Source link